Amneal Pharmaceuticals, Inc. AMRX Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 36.9%+0.4pp | 36.5%+2.2pp | 34.3%-1.2pp | 35.5%-1.3pp | |
| Operating margin | 13.1%+4.1pp | 8.9%+0.4pp | 8.5%— | —— | |
| Net margin | 2.4%+6.6pp | -4.2%-0.7pp | -3.5%+8.0pp | -11.5%— | |
| Free cash flow margin | 8.9%+0.2pp | 8.7%-4.9pp | 13.6%— | —— | |
| Returns | |||||
| Return on assets | 2%+5.4pp | -3.4%-1.0pp | -2.3%+4.3pp | -6.6%— | |
| Return on invested capital | 15.7%+5.2pp | 10.5%+3.1pp | 7.5%+13.7pp | -6.2%-11.5pp | |
| Efficiency | |||||
| Asset turnover | 0.8×0.0× | 0.8×+0.1× | 0.7×+0.1× | 0.6×0.0× | |
| Inventory turnover | 3.1×+0.2× | 3×+0.1× | 2.8×0.0× | 2.8×+0.1× | |
| Liquidity | |||||
| Current ratio | 2.2×+0.8× | 1.4×-0.2× | 1.6×-0.2× | 1.9×-0.4× | |
| Quick ratio | 1.5×+0.6× | 0.9×-0.1× | 0.9×-0.2× | 1.2×-0.4× | |
| Cash ratio | 0.3×+0.2× | 0.1×0.0× | 0.1×+0.1× | 0×-0.3× | |
| Leverage | |||||
| Debt-to-assets | 0.7×0.0× | 0.7×0.0× | 0.7×0.0× | 0.7×0.0× | |
| Per Share | |||||
| Book value per share | -$0.22+38.3% | -$0.35-415% | $0.11-94.3% | $1.98-16.7% | |
| Valuation | |||||
| Market capitalization | $3.96B+61.4% | $2.45B+31.9% | $1.86B+517% | $301.44M-57.9% | |
| Enterprise value | $6.37B+31.7% | $4.84B+12.5% | $4.3B+42.3% | $3.02B-8.6% | |
| Price / earnings | 55×— | —— | —— | —— | |
| Price / sales | 1.3×+0.4× | 0.9×+0.1× | 0.8×+0.6× | 0.1×-0.2× | |
| EV / sales | 2.1×+0.4× | 1.7×-0.1× | 1.8×+0.4× | 1.4×-0.2× | |
| Free cash flow yield | 6.8%-3.1pp | 9.9%-7.6pp | 17.5%— | —— | |
| Earnings yield | 1.8%+6.6pp | -4.8%-0.2pp | -4.5%+80.0pp | -84.5%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Amneal Pharmaceuticals, Inc.'s profit margins?
- Amneal Pharmaceuticals, Inc. (AMRX) runs a 38.7% gross margin and a 14.3% operating margin, with a 4.0% net margin.
- Where do Amneal Pharmaceuticals, Inc.'s ratios come from?
- Every ratio is computed from Amneal Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
